Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Article | By Dr. Rajiv Vaidya and Dr. Samir Acharya, Andelyn Biosciences While recent breakthroughs in gene editing are revolutionizing therapeutic research, delivering therapies to patients will necessitate manufacturers with proven expertise in areas such as viral vector production and analytics. Article | By Justin A. Divan, Pfizer CentreOne A CDMO that can optimize your API synthesis early during technology transfer will reduce the risk of delay or failure.
By Gregory MacMichael, Ph.D., president, CMC Bioservices LLC Biologics development and manufacturing platforms should fit their target product profile. Here are four considerations for building more efficient platforms as part of overarching strategies to shorten path-to-market timelines while protecting quality and safety.
By Gregory MacMichael, Ph.D., president, CMC Bioservices LLC To ensure efficient throughput from drug development to commercialization, drug pipeline companies must structure their processes to control cost and compress timelines without sacrificing quality and safety. In the biopharmaceutical industry, we call this platforming.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
